TheraRadar
← Back
Data updated: Jun 28, 2026

FIDELITY BIOPHARMA

Pharma
Pharmaceuticals

FIDELITY BIOPHARMA is a pharmaceutical company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jan 20, 2027 — Foundayo (orforglipron)

FIDELITY BIOPHARMA's Key Drugs

FIDELITY BIOPHARMA's core commercial portfolio centers on ONTRALFY — its most strategically important drugs approved in the last 15 years.

ONTRALFY
CNS

Spasticity

alpha-2-adrenergic receptor Approved 2024

FIDELITY BIOPHARMA's Recent FDA Approvals

FIDELITY BIOPHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ONTRALFY NDA
2024-12-12
tizanidine hydrochloride
Spasticity

FIDELITY BIOPHARMA's Therapeutic Areas

Disease areas where FIDELITY BIOPHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

FIDELITY BIOPHARMA Pipeline Snapshot

Active clinical trials for FIDELITY BIOPHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ONTRALFY leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling